Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has two wholly-owned ADCs that are on clinical pathways and two high value collaborations with Celgene and Merck Serono. STRO-001 for multiple myeloma and lymphomas is in Ph 1 and expects initial safety data in mid-2019. IND submission for STRO-002 for ovarian and endometrial cancer in Q4 2018 with the initiation of a Ph 1 trial planned for early 2019.
Phase l or ll
100MM - 500MM
Antibodies, Platform Technology
310 Utah Ave
South San Francisco, CA 94080
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by